Form 4: Clene Inc. Director Matthew Kiernan Receives Stock Options

Director Matthew Kiernan was granted 3,376 stock options in Clene Inc. as part of the company's 2020 Stock Plan.

Summary

• Director Matthew Kiernan received two grants of stock options on May 21, 2026.
• The total grant consists of 3,376 shares of common stock with an exercise price of $6.81 per share.
• 1,500 options vest in 12 equal monthly installments starting June 21, 2026.
• 1,876 options vested immediately upon the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Potential dilution of equity value if options are exercised.

Future Outlook

The filing does not provide a forward-looking business outlook, as it is a standard disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term performance and align leadership with shareholder interests in the biotechnology sector.

Comparison to Industry Standards

• The use of the 2020 Stock Plan for director compensation is consistent with standard practices for small-cap biotechnology firms.
• Vesting schedules involving a mix of immediate and monthly installments are common for board members to ensure retention.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new stock options.

Next Steps

• Vesting of 1,500 options in monthly installments beginning June 21, 2026.

Key Dates

Keywords

Clene Inc, CLNN, Form 4, Insider Trading, Stock Options, Director Compensation